The adjusted hazard ratios used a predetermined set of potential confounders that included key demographics, medications at baseline, and identified medical conditions.
All participants completed a basic sociodemographics and medical history questionnaire and reported their list of medications at baseline.
Of note, only four participants (1.3%) were on antihypertensive or dyslipidemia medications at baseline, and this increased to 27 participants (9.1%) at follow-up.
According to the treating physician, ~40% of patients were overusing their headache medications at baseline.
Of the 105 included participants, 21.5% were using preventative medications at baseline.
Furthermore only 50% of patients are using their prescribed preventative medications at baseline.
A headache specialist collected data regarding migraine features, frequency and medications at baseline (T0) and 2 years later (T1).
The non-responder groups were also largely similar to the overall population; although a slightly higher percentage of the non-responders used prophylactic medications at baseline.
Most patients (86%) were using acute headache medications at baseline and 51% other preventive medications; half had received onabotulinumtoxinA for CM before the study.
Among those using acute medications at baseline, 67% (52/78) reduced all acute treatments, 87% (59/68) reduced triptan use, and 79% (34/43) reduced oxygen use by ≥50% compared to baseline.
Patients receiving CC-930 100 mg BID had a higher baseline FVCpercentt of predicted than the other patients and also had a lower history of smoking and required fewer respiratory medications at baseline.
